siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells

@article{Butz2003siRNATO,
  title={siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells},
  author={Karin Butz and Tutik Ristriani and Arnd Hengstermann and Claudia Denk and Martin Scheffner and Felix Hoppe-Seyler},
  journal={Oncogene},
  year={2003},
  volume={22},
  pages={5938-5945}
}
The targeted inhibition of antiapoptotic factors in tumour cells may provide a rational approach towards the development of novel anticancer therapies. Using human papillomavirus (HPV)-transformed cells as a model system, we investigated if RNA interference (RNAi)-mediated gene silencing can be employed in order to overcome the apoptosis resistance of cancer cells. We found that both vector-borne and synthetic small interfering (si)RNAs, specifically directed against the antiapoptotic HPV E6… Expand
RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to Cisplatin
TLDR
It is demonstrated that RNAi against E6 and E7 oncogenes enhances the chemotherapeutic effect of cisplatin in HeLa cells, probably because of increased p53 levels. Expand
Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA
TLDR
It is suggested that E 6-specific suppression may induce more potent anticancer activity than simultaneous E6 and E7 suppression, and that E6-specific targeting is a promising strategy for siRNA-based therapy for HPV-positive cervical cancer. Expand
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer
TLDR
This review discusses what is currently known about HPV-associated carcinogenesis and the potential for combining siRNA with other treatment strategies for the development of future therapies, and presents the assessment of the most promising path to theDevelopment of RNAi therapeutic strategies for clinical settings. Expand
Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.
High-risk human papillomavirus (HPV) types 16 and 18 are associated with more than 70% of cervical cancer cases. The oncoprotein E6 is multifunctional and has numerous cellular partners. TheExpand
Silencing of hpv16 e6 and e7 oncogenic activities by small interference rna induces autophagy and apoptosis in human cervical cancer cells
TLDR
It is suggested that selective silencing of HPV16 E6 and E7 oncogenes by siRNAs, has significant biological effects on the survival of human cancer cells and is a potential gene therapy strategy against cervical cancer. Expand
Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
TLDR
It is shown that lentivirus delivered short-hairpin RNA (shRNA) against human papillomavirus (HPV) E6/E7 oncogenes were effective for only 2 weeks in a cervical cancer model, and that a multi-shRNA strategy may be a more attractive approach for developing an RNAi therapy for this cancer. Expand
Future of RNAi-based therapies for human papillomavirus-associated cervical cancer
TLDR
This review will discuss potential gene-silencing strategies in cervical cancer that would target both viral genes such as E6 and E7, and cellular genes that become deregulatedsuch as E2F, p53, Akt, mTor, NF-κB or Bcl-2. Expand
The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets.
TLDR
Hypoxic HPV-positive cancer cells could be a major obstacle for treatment strategies targeting E6/E7 since they downregulate E6 /E7 but evade senescence through hypoxia-induced mTOR impairment, and prospective E6-E7 inhibitors may benefit from a combination with treatment strategies directed against hypoxic tumor cells. Expand
Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation.
TLDR
This study tried photodynamic antisense regulation of the antiapoptotic E6 expression using a photocross-linking reagent and effectively elicited the apoptotic death of HPV18-positive cervical cancer cells through the selective repression of E6 mRNA and consequent stabilization of p53 protein. Expand
Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA
TLDR
The results indicate that the activity of E6 oncoprotein can be down-regulated in vivo by lipid-mediated antibody delivery and that antibodies and siRNA act synergistically when codelivered. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference
TLDR
It is demonstrated for the first time that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression. Expand
Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.
TLDR
These results provide direct experimental evidence that the HPV E6 oncoprotein has antiapoptotic activity in HPV-positive tumor cells that is required for their survival. Expand
Papillomavirus E2 induces senescence in HPV‐positive cells via pRB‐ and p21CIP‐dependent pathways
TLDR
It is shown that the E2‐mediated growth arrest of HPV‐positive cells results in cellular senescence, and implicate the cyclin/cdk inhibitor p21CIP as a downstream E2 effector in this phenotype. Expand
Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
  • E. Goodwin, D. DiMaio
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2000
TLDR
This dynamic response strongly suggests that the p53 and Rb tumor suppressor pathways are intact in HeLa cells and that repression of HPV E6 and E7 mobilizes these pathways in an orderly fashion to deliver growth inhibitory signals to the cells. Expand
Stable suppression of tumorigenicity by virus-mediated RNA interference.
TLDR
Viral delivery of small interfering RNAs can be used for tumor-specific gene therapy to reverse the oncogenic phenotype of cancer cells, and this work uses a retroviral version of this vector to specifically and stably inhibit expression of only the onCogenic K-RAS(V12) allele in human tumor cells. Expand
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
TLDR
It is demonstrated that the E6 proteins of the oncogenic HPVs that bind p53 stimulate the degradation of p53, which results in selective degradation of cellular proteins such as p53 with negative regulatory functions provides a novel mechanism of action for dominant-acting oncoproteins. Expand
The role of the E6-p53 interaction in the molecular pathogenesis of HPV
TLDR
Like all viral oncoproteins, E6 is a multifunctional protein and a plethora of other cellular targets has been identified, and E6's interactions with some of these additional targets appear to be equally important in the pathogenesis of HPV, and may also represent valid targets for therapeutic intervention. Expand
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
TLDR
Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies by enhancing the antitumor activity of Apo-2L/tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) in an intracranial malignant glioma xenograft model in vivo. Expand
Inhibition of Bak-induced apoptosis by HPV-18 E6
TLDR
It is shown that HPV-18 E6 will inhibit Bak-induced apoptosis and this is mediated by an interaction between the E6 and Bak proteins resulting in degradation of the Bak protein in vivo. Expand
Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development.
TLDR
A similarity between the mechanism regulating E7-induced, p53-independent apoptosis and the apoptotic-like developmental process of fiber cell denucleation is suggested, and the mechanisms through which E6 suppresses both processes are suggested. Expand
...
1
2
3
4
5
...